[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"catheter-ablation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:catheter-ablation":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,18,0,[8,47,81,105,133,166,192,221,244,265,297,322,351,376,404,451,474,497],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100414564","zero-fluoroscopy-voltage-guided-vs-linear-cti-ablation-100414564",false,"NCT04678258","Zero Fluoroscopy Voltage Guided vs. Linear CTI Ablation","A Zero Fluoroscopy Maximum Voltage Guided Stepwise Approach Using IntellaMiFi Technology Compared to Linear Ablation of the Cavotricuspid Isthmus for Typical Atrial Flutter: the ZERO MAGIC Trial","ZERO MAGIC","Inclusion Criteria:\n\n* Typical (CTI dependent) atrial flutter documented in a standard 12 lead surface ECG\n* Given class I indication for curative CTI ablation according to the current guidelines\n* Over 18 years old\n* Given informed consent\n\nExclusion Criteria:\n\n* Any contraindication for CTI ablation\n* Previous CTI ablation\n* BCB as procedural endpoint not assessable\n* CTI ablation conducted in association with further ablation procedures\n* Patients with CIED (e.g. pacemaker, ICD)\n* Tricuspid valve replacement\n* Right atrial thrombus\n* Pregnant or breastfeeding women\n* Abuse of drugs or alcohol\n* Age \\\u003C 18 years\n* Incompliance to the treatment, e.g. necessary anticoagulation\n* Expected survival less than one year\n* Inability to understand the nature and rationale of the study\n* Inability to take part in the follow up","ALL","18 Years",{"count":20,"type":21},106,"ESTIMATED","INTERVENTIONAL",[24],"NA","Catheter ablation of the cavo-tricuspid isthmus (CTI) is the curative first-line therapy for typical atrial flutter. Currently, two approaches are used in clinical practice. In contrast to the conventional linear ablation approach, the Maximum voltage-guided (MVG) strategy aims to limit ablation to high voltage areas (HVAs) representing the detectable correlate of relevant conducting bundles. Data from registries show that the MVG technique is sufficient to reach comparable clinical outcome with significantly shorter ablation duration when compared to the conventional linear strategy.\n\nDespite growing evidence, however, data from properly powered prospective randomized trials are lacking and the linear approach still remains standard. In addition, data on radiation exposure are controversial.\n\nAs a substrate-based approach, the MVG strategy requires detailed mapping and signal analysis for identification of the individual architecture and exactly targeted energy application. However, the spatial mapping resolution of large tip catheters is limited. The use of the MicroFidelity catheter technology (IntellaMiFi) with high resolution mini-electrodes at the 8 mm catheter tip can be expected to further improve the feasibility of a voltage-guided approach. In addition, the MVG approach theoretically may encompass an increased risk for clinically inapparent reconduction. A prospective study with predefined invasive re-evaluation of persistent CTI block is needed to further evaluate this issue.\n\nObjective of this prospective randomized study is evaluate the performance of the micro-sensor technology for zero-fluoroscopy voltage-guided ablation of typical atrial flutter (AFL) compared with a population undergoing conventional linear ablation including a predefined invasive re-evaluation of persistent CTI block in addition to clinical follow-up.\n\nThe study has been approved by the responsible ethics committee.",[27,28,29],"Catheter Ablation","Atrial Flutter Typical","Radiation Exposure",[31,32,33],"atrial flutter typical","catheter ablation","electroanatomic mapping","RECRUITING","2026-06-12",{"date":37,"type":38},"2026-06-15","ACTUAL",{"date":40,"type":38},"2020-11-30",{"date":42,"type":21},"2027-08-31",{"name":44,"class":45},"Klinikum-Fuerth","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":59,"conditions":60,"keywords":67,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":46},"100626880","catheter-ablation-plus-laao-versus-anticoagulation-in-frail-elderly-patients-with-atrial-fibrillation-100626880","NCT07441382","Catheter Ablation Plus LAAO Versus Anticoagulation in Frail Elderly Patients With Atrial Fibrillation","Randomized Controlled Trial - Catheter Ablation Combined With Left Atrial Appendage Occlusion Versus Catheter Ablation Combined With Oral Anticoagulation for Elderly Frailty Patients With Atrial Fibrillation: Comparison of Efficacy and Safety","CLEAR-AF","Inclusion Criteria: (1) Age ≥ 75 years. (2) Confirmed diagnosis of non-valvular atrial fibrillation (paroxysmal or persistent). (3) CHA2DS2-VASc score ≥ 3 (high risk of stroke) . (4) Procedure-related criteria: Sequential Group: Participants who have received catheter ablation for non-valvular AF within 90 to 180 days prior to randomization. One-stop Group: Participants who are scheduled to undergo clinically indicated catheter ablation within 10 days after randomization. (5) Judged by the investigator to be able to tolerate the defined antithrombotic drug regimen. (6) Suitable to undergo Transesophageal Echocardiography (TEE) or Pulmonary Vein Computed Tomography (CT). (7) Able and willing to sign the written informed consent form. (8) Willing to return for all scheduled follow-up visits and examinations. Exclusion Criteria: (1) Presence of thrombus in the left atrium or left atrial appendage identified on preoperative imaging (echocardiogram, pulmonary vein CT, etc). (2) Major bleeding event (per ISTH definition) within 14 days prior to randomization. Participants must be excluded if clinical sequelae persist or if interventions for the bleeding source are planned\u002Fpending, regardless of the time elapsed since the event. (3) Requirement for long-term oral anticoagulation (OAC) for reasons other than stroke risk reduction in AF (e.g., underlying hypercoagulable state) that would prevent OAC discontinuation post-device implantation. (4) Any cardiac or major non-cardiac intervention\u002Fsurgery (excluding AF ablation and cardioversion) performed within 30 days prior to, or scheduled within 60 days after randomization. This includes but is not limited to Percutaneous Coronary Intervention (PCI) or other cardiac ablations. (5) Life expectancy \\\u003C 2 years, malignancy, infectious endocarditis, uncontrolled infection, or physiological evidence of cardiac tamponade. (6) Clinical Frailty Scale (CFS) score of 1-3 (not frail) or 7-9 (severely frail\u002Fterminally ill). (7) Deemed unsuitable for long-term anticoagulation and\u002For antiplatelet therapy by the investigator due to bleeding risk, allergies, or other reasons. (8) Current participation in another clinical trial that interferes with this study, excluding mandatory government or purely observational registries. (9) Stroke or transient ischemic attack (TIA) within 60 days prior to randomization. (10) Documented myocardial infarction (NSTEMI or STEMI) within 90 days prior to randomization, regardless of intervention. (11) History of atrial septal defect (ASD) repair or presence of an ASD\u002FPatent Foramen Ovale (PFO) occluder. (12) Presence of a mechanical prosthetic valve in any position. (13) Participants of childbearing potential who are pregnant or planning pregnancy during the study period. (14) Medical or anatomical contraindications to percutaneous catheter-based interventions. (15) Documented NYHA Class IV heart failure. (16) History of surgical left atrial appendage (LAA) closure.\n\nTransthoracic Echocardiography (TTE) Specific Exclusions: (1) Low LVEF: Left ventricular ejection fraction (LVEF) \\\u003C 30%. (2) Presence of pericardial effusion with a circumferential echo-free space \\> 5mm. (3) Presence of high-risk PFO associated with an atrial septal aneurysm (ASA) with an excursion or length \\> 15mm. (4) Presence of high-risk PFO with a large shunt (defined as appearance of microbubbles within 3 cardiac cycles and\u002For a substantial count of microbubbles). (5) Presence of moderate or severe mitral stenosis (mitral valve area \\\u003C 1.5 cm2).","75 Years",{"count":57,"type":21},200,[24],"Atrial fibrillation (AF) is the most common arrhythmia, significantly increasing the risk of stroke, heart failure, hospitalization and death in patients. Studies have shown that standardized anticoagulation can effectively reduce the risk of stroke by 64% and the risk of death by 26% in AF patients. Therefore, both European and American guidelines recommend standardized oral anticoagulation (OAC) as an important treatment strategy for stroke prevention in AF patients. However, the use of OAC may also increase the risk of bleeding in patients. Results from large AF anticoagulation randomized trials show that the annual risk of anticoagulation-related bleeding mortality is 2% to 3%. Therefore, according to the guidelines recommendations, assessing the bleeding risk is necessary in patients with anticoagulant indications.\n\nPercutaneous left atrial appendage occlusion (LAAO) is a device-based therapy that aims to prevent ischemic stroke in patients with AF. For patients with contraindications to long-term anticoagulation therapy, LAAO can be considered as an alternative strategy to oral anticoagulation (Class II B recommendation) to prevent ischemic stroke and thromboembolism. Multiple studies have shown that LAAO is non-inferior to warfarin and novel oral anticoagulants in stroke prevention for non-valvular AF patients. Age is not only a risk factor for stroke but also an important risk factor for bleeding. In the elderly population, especially those with frailty, the risk factors for both stroke and bleeding are often increased. Currently, there is insufficient evidence to support the use of OAC in frail elderly patients with relative anticoagulant contraindications. Therefore, elderly AF patients may be one of the potential beneficiary groups for LAAO. However, most previous clinical studies on LAAO were based on small sample sizes to analyze their safety and efficacy, and clinical data on the safety and efficacy of LAAO in this high-risk population of elderly AF patients are still limited. To address this, the study aims to conduct a multicenter randomized controlled trial to compare the efficacy and safety of catheter ablation combined with LAAO versus catheter ablation combined with OAC in elderly AF patients with high bleeding risk, filling the gap in this research area.\n\nTo address these limitations, this multicenter randomized controlled trial is designed to evaluate the efficacy and safety of catheter ablation combined with LAAO versus catheter ablation combined with OAC in elderly AF patients at high risk for bleeding. The primary objective of the study is to compare the 12-month incidence and time-to-occurrence of the composite clinical endpoint. This endpoint includes stroke\u002FTIA, systemic embolism, ISTH-defined major bleeding. By establishing these metrics within the first year, the study aims to fill the current void in clinical evidence and provide a standardized treatment strategy for high-risk elderly patients. In addition to the primary endpoints, the study will conduct a comprehensive long-term evaluation extending to 24 months post-procedure to assess the durability of both treatment strategies. Secondary objectives include the assessment of perioperative safety, specifically focusing on serious intraoperative complications and major adverse events occurring within the first seven days after the LAAO procedure. The trial will also measure long-term rhythm control by tracking the rate of freedom from AF recurrence at the one-year and two-year marks. Furthermore, the study seeks to verify the hypothesized superiority of the ablation-plus-LAAO strategy in reducing the specific burden of anticoagulation-related major bleeding and stroke.\n\nBeyond clinical safety and efficacy, the trial will analyze the practical aspects of the two interventions, including procedural success rates, operation duration, fluoroscopy time, and the total duration of hospitalization. A critical component of the research involves identifying specific risk factors associated with complications, with a specialized focus on how frailty scores influence procedural tolerance and long-term prognosis. The study will further explore how different types of AF respond to the LAAO strategy and assess the impact of each treatment on non-major bleeding events. Ultimately, the trial aims to determine which strategy offers a superior improvement in the overall quality of life for elderly patients, thereby optimizing future clinical guidelines.",[61,62,63,64,65,27,66],"Atrial Fibrillation (AF)","Stroke","Hemorrhage","Frailty","Atrial Appendage","Anticoagulants",[68,69,62,63,66,64,70,71,27],"Atrial Fibrillation","Left Atrial Appendage Closure","Aged","Randomized Controlled Trial","2026-06-05",{"date":74,"type":38},"2026-06-08",{"date":76,"type":38},"2026-03-24",{"date":78,"type":21},"2028-03-01",{"name":80,"class":45},"Guangdong Provincial People's Hospital",{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":22,"phases":91,"briefSummary":92,"conditions":93,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":104},"100425693","randomized-controlled-trial--ablation-strategy-for-paroxysmal-atrial-fibrillation---trigger-and-substrate-guided-wide-area-radiofrequency-ablation-compared-to-pulsed-field-ablation-pulmonary-vein-isolation-100425693","NCT04823299","Randomized Controlled Trial- Ablation Strategy for Paroxysmal Atrial Fibrillation - Trigger and Substrate Guided Wide Area Radiofrequency Ablation Compared to Pulsed Field Ablation Pulmonary Vein Isolation","AWARE-2 - Randomized Controlled Trial Ablation Strategy for Paroxysmal Atrial Fibrillation - Trigger and Substrate Guided Wide Area Radiofrequency Ablation Compared to Pulsed Field Ablation Pulmonary Vein Isolation","AWARE-2","Inclusion Criteria:\n\n1. Age ≥18 years on the date of consent for the trial.\n2. Subjects must have paroxysmal AF with at least one episode of AF over the past 12 months (patients on antiarrhythmic medications do not need to satisfy this criterion).\n\n   At least one episode of AF documented on 12-lead ECG, Holter monitor, Trans-telephonic monitor (TTM) or Loop Recorder.\n3. Subjects must be able to provide informed consent.\n\nExclusion Criteria:\n\n1. Persistent and permanent AF.\n2. History of previous catheter or surgical ablation for AF, AFl, AT, Atrioventricular Nodal Reentrant Tachycardia (AVNRT), Atrioventricular Reentrant Tachycardia (AVRT).\n3. Documented AVNRT, AVRT, AT or Atrial Flutter prior to enrolment in the trial.\n4. Previous left atrial (LA) ablation or LA surgery.\n5. Previous pulmonary vein stenosis or pulmonary vein stent.\n6. Pre-existing hemi-diaphragmatic paralysis.\n7. Active intracardiac thrombus.\n8. Contraindication to systemic oral anticoagulation therapy\n9. Current immunosuppressant therapy (corticosteroids, biologic immunomodulators; such patients may be considered if they can safely discontinue immunosuppressants for three months prior to and for three months following catheter ablation).\n10. Reversible causes of AF (e.g., uncontrolled hyperthyroidism, within six months of cardiac surgery).\n11. Left ventricular ejection fraction \\\u003C35%.\n12. NYHA Class 4 heart failure.\n13. Hypertrophic cardiomyopathy\n14. Significant valve disease (moderate or severe mitral\u002Faortic stenosis or regurgitation).\n15. Patients with mechanical mitral prosthetic valves\n16. Known adverse reaction to adenosine.\n17. Chronic Kidney Disease ≥ Stage 4.\n18. Significant congenital heart disease (including atrial septal defects or pulmonary vein abnormalities; however, subjects with patent foramen ovale will not be excluded).\n19. Pregnant subjects.\n20. Cerebral ischemic event (stroke or transient ischemic attack) in the six months prior to consenting for the trial.\n21. History of thromboembolic events in the 6 months preceding enrollment.\n22. Currently participating or anticipated to participate in interventional clinical trials of drug, device or biologic agents that could affect the results of this trial.\n23. Primary pulmonary hypertension\n24. Rheumatic heart disease\n25. Thrombocytosis, thrombocytopenia and other hypercoagulable states\n26. Active systemic infection\n27. Patients with life expectancy less than 12 months.\n28. Unwilling or unable to comply fully with study procedures and follow-up.",{"count":90,"type":21},556,[24],"Atrial fibrillation (AF) is a common heart rhythm disorder affecting over a million people in North America and is associated with serious complications including stroke, heart failure, reduced quality of life, and premature death. Catheter ablation has been shown to be more effective than medications for controlling symptoms and reducing the risk of these complications; however, recurrence of AF after ablation remains a significant challenge, often due to incomplete or ineffective initial procedures. This clinical trial aims to determine whether a novel, patient-tailored ablation strategy can improve outcomes compared to the current standard-of-care approach. Participants will be randomly assigned to undergo either standard pulmonary vein isolation or a more individualized ablation procedure that identifies and targets patient-specific sources of AF. All participants will undergo the ablation procedure, receive continuous heart rhythm monitoring, and be followed over time to assess recurrence and safety outcomes.",[68,27,94],"Radiofrequency Catheter Ablation","2026-04-23",{"date":97,"type":38},"2026-04-29",{"date":99,"type":38},"2026-03-23",{"date":101,"type":21},"2030-03",{"name":103,"class":45},"Ottawa Heart Institute Research Corporation",2,{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":113,"enrollmentInfo":114,"targetDuration":4,"studyType":22,"phases":116,"briefSummary":117,"conditions":118,"keywords":120,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":132},"100584017","efficacy-and-safety-of-catheter-ablation-in-patients-with-severe-mitral-regurgitation-and-persistent-atrial-fibrillation-a-randomized-controlled-trial-100584017","NCT06883864","Efficacy and Safety of Catheter abLation in patiEnts With seVere mitrAl regurgiTation and pErsistent Atrial Fibrillation: a Randomized Controlled Trial","Efficacy and Safety of Catheter abLation in patiEnts With seVere mitrAl regurgiTation and pErsistent Atrial Fibrillation: a Randomized Controlled Trial(ELEVATE-AF)","ELEVATE-AF","Inclusion Criteria:\n\n1. Patients were required to have moderate-to-severe or greater (≥3+) atrial functional mitral regurgitation assessed by transthoracic echocardiography within 14 days before randomization. Mitral regurgitation severity was graded by an echocardiography core-lab based on the American Society of Echocardiography criteria, specifically an effective regurgitant orifice area (EROA) ≥30 mm²\n2. Age 18-80 years\n3. Persistent atrial fibrillation diagnosed by electrocardiogram\n4. Left ventricular ejection fraction ≥50% assessed by transthoracic echocardiography within 14 days before randomization(confirmed by the echocardiography core-lab)\n5. Left ventricular end-diastolic internal diameter ≤60 mm and left atrial anterior- posterior diameter ≤60 mm in echocardiographic parasternal long-axis view within 14 days before randomization(confirmed by the echocardiography core-lab)\n6. Agree to undergo catheter ablation and be able to undergo follow-up as required.\n\nExclusion Criteria:\n\n1. paroxysmal atrial fibrillation, atrial fibrillation secondary to an apparently reversible cause, or with history of previous ablation;\n2. primary mitral valve pathology, including calcification, sclerosis, prolapse, flail, tendon cable rupture, valve degeneration, infective endocarditis, rheumatic lesions, or ischemic lesions;\n3. history of previous mitral valve surgery or transcatheter manipulation;\n4. mitral valve orifice area \\\u003C4 cm2;\n5. aortic valve disease requiring surgical or transcatheter intervention;\n6. untreated clinically significant coronary artery disease requiring revascularization;\n7. history of previous myocardial infarction;\n8. previous definitive diagnosis of cardiomyopathies such as dilated cardiomyopathy, hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, arrhythmogenic cardiomyopathy, and infiltrative cardiomyopathies (e.g., amyloidosis, hemochromatosis, and nodular disease)\n9. echocardiographic evidence of intracardiac mass or thrombus;\n10. implant of cardiac device (pacemaker, implantable cardioverter defibrillator, cardiac resynchronization therapy device, or left atria appendage closure);\n11. hemodynamic instability requiring cardiac assist devices, intra-aortic balloon pump (IABP), or other hemodynamic support;\n12. any percutaneous cardiac intervention (percutaneous coronary intervention, transcatheter aortic valve replacement, etc.) within the 30 days prior to randomization,\n13. any cardiac surgery within the 6 months prior to randomization;\n14. active infections requiring current antibiotic therapy;\n15. a known hypersensitivity or contradiction to procedure medications which cannot be adequately managed medically;\n16. contraindication to appropriate anti-coagulation therapy;\n17. chronic obstructive pulmonary disease (COPD) requiring continuous home oxygen therapy or chronic oral steroid therapy;\n18. acute cerebrovascular accident within 30 days prior to randomization or Modified Rankin Score ≥ 4;\n19. symptomatic severe carotid stenosis (\\>70% by ultrasound);\n20. other planned surgical or interventional procedures within the next 3 months;\n21. liver failure;\n22. renal failure or dialysis status;\n23. pregnant or planning pregnancy within the next 3 months;\n24. life expectancy \\\u003C 12 months (e.g., advanced malignant tumors);\n25. currently participating in other interventional studies;\n26. circumstances that, in the judgment of the researcher, make participation in this study unsuitable.","80 Years",{"count":115,"type":21},146,[24],"Atrial fibrillation (AF) leads to atrial functional mitral regurgitation (MR) through mechanisms including mitral annular dilatation, systolic leaflet motion distance alteration, and contractility decrease. Compared with primary MR, atrial functional MR due to AF and other diseases tends to have a worse prognosis, with a higher risk of death and heart failure hospitalization. MR and AF co-exist and exacerbate left atrial dysfunction, further causing worse cardiac dysfunction, valvular regurgitation, and aggravating prognosis.\n\nThe best therapy for secondary MR is unclear because MR is only one component of the disease, and restoration of mitral valve competence is not curative. Catheter ablation improves symptoms and cardiac function in patients with AF, reduces risks of AF recurrence and hospitalization, as well as increases quality of life. For patients with AF combined with functional moderate-to-severe MR, previous observational studies have found that the severity of MR significantly reduced after taking catheter ablation to restore sinus rhythm. We hypothesized that catheter ablation would significantly improve the severity of MR in patients with severe atrial functional MR combined with persistent AF compared with drug therapy alone.",[61,27,119],"Atrial Functional Mitral Regurgitation",[121,122,32],"atrial fibrillation","mitral regurgitation","2026-03-11",{"date":125,"type":38},"2026-03-13",{"date":127,"type":38},"2025-04-08",{"date":129,"type":21},"2028-05-01",{"name":131,"class":45},"Beijing Anzhen Hospital",17,{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":140,"targetDuration":4,"studyType":22,"phases":142,"briefSummary":145,"conditions":146,"keywords":152,"overallStatus":155,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":4},"100620611","phase-1-relaxin-therapy-for-atrial-fibrillation-100620611","NCT07359872","Relaxin Therapy for Atrial Fibrillation","Relax-in-AF","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Diagnosed with AF and scheduled for elective catheter ablation for AF\n\nExclusion Criteria:\n\n* Enrollment in another Greater than Minimal Risk Study\n* Pregnant, nursing, or sexually active females not using birth control or having been surgically sterilized\n* Females who plan to become pregnant during the trial period\n* Patients diagnosed with \"permanent\" AF, complete heart block, or a reversible cause of AF (e.g., transient thyrotoxicosis)\n* Patients that require antiarrhythmic medication to started or continued during and after the ablation procedure.\n* Patients unable to tolerate Relaxin therapy or unable or unwilling to provide informed consent",{"count":141,"type":21},208,[143,144],"PHASE1","PHASE2","Atrial fibrillation (AF) is the most common heart rhythm disorder. The presence of AF increases the risk of death and is associated with a 5-6-fold increase in stroke incidence, due almost exclusively to thrombus formation in the heart. Current therapies for AF are limited. The evaluation of new, more effective treatments for preventing AF recurrence remains a critical unmet clinical need. AF is considered a progressive disease that increases in prevalence with age and can convert from \"paroxysmal\" to \"persistent\" to \"permanent\" AF in a single individual. This progression results, in part, from high oxidative stress and progressive adverse electrical changes in the heart. Compelling preclinical and clinical data indicate that Relaxin, a naturally occurring peptide hormone, may reverse the electrical remodeling. Thus, our overall objective is to investigate the effects of Relaxin in Veterans who have failed medical management for symptomatic AF and is referred to Cardiac Electrophysiology Laboratory for catheter ablation and pulmonary vein isolation. We will determine whether Relaxin therapy, in addition to the standard of care, counteracts the oxidative stress-related electrical derangement and reduces the post-ablation AF burden. A unique aspect of this proposal is that it is based in part on observations derived from the basic, translational and computational labs of the PI and co-investigators and from the observations by the PI while caring for patients with AF. As such, this proposal represents a true progression from the bench to the bedside. If successful, our findings may lead to the design of a new, more effective treatment for a major unmet public health problem in the United States as well as the world.",[61,147,148,62,149,150,27,151],"Arrhythmia","Oxidative Stress","Major Cardiovascular Event","Heart Failure","Ablation of Atrial Fibrillation",[153,154],"randomized controlled crossover trial","Randomized clinical trial","NOT_YET_RECRUITING","2026-01-21",{"date":158,"type":38},"2026-01-22",{"date":160,"type":21},"2027-01-01",{"date":162,"type":21},"2030-12-31",{"name":164,"class":165},"Deeptankar DeMazumder","FED",{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":172,"eligibilityCriteria":173,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":174,"targetDuration":4,"studyType":22,"phases":176,"briefSummary":177,"conditions":178,"keywords":179,"overallStatus":155,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":4},"100611176","prombot-hsm-fa-protocol-for-a-feasibility-study-of-a-chatbot-platform-to-collect-patient-reported-outcomes-after-af-ablation-100611176","NCT07237178","PROMBot-HSM-FA: Protocol for a Feasibility Study of a Chatbot Platform to Collect Patient-reported Outcomes After AF Ablation","PROMBot-HSM-FA: Protocol for a Feasibility Study of a Chatbot-based Platform to Collect Patient-reported Outcomes After Atrial Fibrillation Ablation","PROMBot-HSM-FA","Inclusion Criteria:\n\n* age 18 years or older;\n* documented diagnosis of paroxysmal or persistent AF based on clinical assessment and coded according to the International Classification of Diseases, 11th Revision;\n* undergone catheter ablation for AF at Hospital de Santa Marta during the study recruitment period;\n* able to use the PROMBot-FA chatbot independently or with caregiver assistance, defined as Portuguese literacy sufficient to understand instructions and ability to operate a smartphone;\n* clinically stable at discharge with no acute post-procedural complications precluding participation; and\n* provision of written informed consent.\n\nExclusion Criteria:\n\n* severe cognitive impairment preventing comprehension of study procedures, such as moderate-to-severe dementia or other neurological conditions limiting capacity to consent;\n* severe uncorrected visual impairment or motor disability preventing smartphone operation even with caregiver support;\n* explicit refusal to use digital technology or unwillingness to share health data required for the study;\n* clinical or contextual conditions rendering 3-month follow-up unfeasible, including anticipated relocation outside the hospital catchment area or concurrent participation in another interventional study with overlapping endpoints; or\n* life expectancy less than 6 months.",{"count":175,"type":21},76,[24],"The goal of this clinical trial is to learn if using a WhatsApp-based chatbot called PROMBot-FA can help people recover after atrial fibrillation ablation. The main questions it aims to answer are:\n\n* Is the chatbot easy and practical for people to use after their procedure?\n* Do people find the chatbot helpful for sharing their symptoms and health updates?\n\nResearchers will compare follow-up care supported by the chatbot to standard hospital follow-up visits. Participants will:\n\n* Be randomly assigned to either use the chatbot or receive usual follow-up care.\n* Report their symptoms, well-being, and any problems after ablation for 3 months.\n* Complete short questionnaires about their experience using the chatbot.\n\nThis study will help researchers understand whether chatbot follow-up is feasible and acceptable for people after atrial fibrillation ablation and guide future larger studies.",[61,27],[121,32,180,181,182],"postoperative care","telemedicine","Patient Reported Outcome Measures","2025-11-20",{"date":185,"type":38},"2025-11-26",{"date":187,"type":21},"2025-12-01",{"date":189,"type":21},"2027-12",{"name":191,"class":45},"Ana Rita Londral, PhD",{"id":193,"slug":194,"hasResults":11,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":198,"eligibilityCriteria":199,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":200,"targetDuration":4,"studyType":22,"phases":202,"briefSummary":203,"conditions":204,"keywords":207,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":46},"100596574","substrate-remodelling-and-targeted-ablation-in-af-100596574","NCT07047235","Substrate Remodelling and Targeted Ablation in AF","Understanding Substrate Evolution in Persistent Atrial Fibrillation to Develop Tailored Ablation Strategies","STRATA-AF","Inclusion Criteria:\n\n* Able and willing to provide written informed consent\n* Age: 18 years or older\n* Clinical diagnosis: Persistent atrial fibrillation\n* Treatment status: Scheduled to undergo first-time catheter ablation for persistent AF\n\nExclusion Criteria:\n\n* Inability or unwillingness to provide informed consent\n* Under 18 years of age\n* Previous left atrial ablation for AF or other atrial arrhythmias\n* Any clinical contraindications to undergoing AF catheter ablation",{"count":201,"type":21},160,[24],"Atrial fibrillation (AF) is the most common heart rhythm disorder, affecting millions worldwide and causing symptoms such as palpitations, fatigue and breathlessness. It also increases the risk of stroke and heart failure, so effective treatment is essential.\n\nA treatment for AF involves catheter ablation, a minimally invasive procedure where problematic areas of the heart are targeted using controlled energy. This is done by passing wires called catheters, through blood vessels at the top of the leg all the way to the heart. However, this isn't effective for everyone and approximately half of patients experience a return of AF despite treatment.\n\nIn this researcher-led study at St Bartholomew's Hospital , the investigators will use a method called electroanatomical mapping to make a 3D picture of the left atrium, the heart's upper left chamber. To make this picture more detailed, information will be collected - such as how strong electrical signals are (voltage), how fast and in which direction they travel through the heart to describe abnormal areas and areas of scar within the heart. Information will also be gathered about the routes electricity takes and the nerve activity in the heart muscle. These detailed maps will help to understand why AF can continue indefinitely in some people, why ablation works for some people and not others, and improve how ablations are done to make them more effective.\n\nAll participants will undergo catheter ablation with these mapping methods integrated into the procedure. If AF recurs, patients will be invited for a second ablation targeting specific abnormal areas depending on the amount of scar found. This will be standardised across patients.\n\nPatients will be followed for 12 months, with structured visits at 3, 6, 9 and 12 months and 48-hour ECG recorders at 6 and 12 months. By tracking how the heart's structure and electrical behaviour evolve, the aim is to to see if map-guided ablation reduces the need for further procedures, lowers healthcare costs and improves quality of life.\n\nUltimately, this study will provide clear, reproducible insights into AF mechanisms and yield practical guidance so clinicians can predict who will benefit from standard ablation treatment and who may require extra, map-guided treatment.",[61,205,27,206],"Atrial Fibrillation Mechanisms","Low Voltage Areas",[208,209,210,211],"ganglionic plexi","autonomic remodelling","substrate remodelling","conduction velocity","2025-11-17",{"date":214,"type":38},"2025-11-18",{"date":216,"type":38},"2025-11-07",{"date":218,"type":21},"2030-08-18",{"name":220,"class":45},"Barts & The London NHS Trust",{"id":222,"slug":223,"hasResults":11,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":227,"eligibilityCriteria":228,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":229,"enrollmentInfo":230,"targetDuration":4,"studyType":22,"phases":231,"briefSummary":232,"conditions":233,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":243,"locationsCount":46},"100523481","investigation-of-cardioversion-versus-therapeutic-ablation-for-persistent-af-orbica-af-100523481","NCT06096246","Investigation of Cardioversion Versus Therapeutic Ablation for Persistent AF (ORBICA-AF)","Objective Randomised Blinded Investigation of Cardioversion Versus Ablation for Persistent Atrial Fibrillation (ORBICA-AF)","ORBICA-AF","Inclusion Criteria:\n\n* Ability to give informed consent\n* Age 18-85 years\n* Persistent AF (atrial fibrillation lasting \\> 7days) of total continuous duration \\\u003C2 years as documented in medical notes.\n* Patients being considered for cardioversion.\n\nExclusion Criteria:\n\n* Creatinine clearance (eGFR) \\\u003C 30mls\u002Fmin\n* Contraindication or unable to take anticoagulation\n* Uncontrolled hypertension\n* Contraindication for catheter ablation\n* BMI \\> 40\n* Patients in Persistent AF who have had more than one previous cardioversion.\n* Established diagnosis of Hypertrophic cardiomyopathy","85 Years",{"count":141,"type":21},[24],"The main aim of the research is to investigate whether patients undergoing pulmonary vein isolation with catheter ablation for persistent atrial fibrillation (AF) will have lower rates of AF recurrence than those treated by DC cardioversion without an ablation procedure.",[234,235,27],"Persistent Atrial Fibrillation","Cardiac Arrhythmia","2025-09-01",{"date":238,"type":38},"2025-09-03",{"date":240,"type":38},"2024-07-26",{"date":242,"type":21},"2027-12-05",{"name":220,"class":45},{"id":245,"slug":246,"hasResults":11,"nctId":247,"briefTitle":248,"officialTitle":249,"acronym":4,"eligibilityCriteria":250,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":113,"enrollmentInfo":251,"targetDuration":4,"studyType":22,"phases":253,"briefSummary":254,"conditions":255,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":260,"completionDateStruct":261,"leadSponsor":263,"locationsCount":46},"100589387","effects-of-music-during-atrial-fibrillation-ablation-under-conscious-sedation-100589387","NCT06953752","Effects of Music During Atrial Fibrillation Ablation Under Conscious Sedation","Effects of Music on Pain and Anxiety During Atrial Fibrillation Ablation Under Conscious Sedation: A Randomized Controlled Trial","Inclusion Criteria:\n\n1. Patients undergoing first-time catheter radiofrequency ablation for atrial fibrillation at our center according to guideline recommendations;\n2. Aged 18-80 years;\n3. Willing to participate in the study and providing signed informed consent.\n\nExclusion Criteria:\n\n1. Active psychiatric conditions necessitating pharmacotherapy;\n2. Auditory\u002Fcognitive barriers to protocol compliance;\n3. General anesthesia candidates;\n4. Hybrid AF procedures (e.g., concomitant LAA occlusion);\n5. Previous cardiac interventions;\n6. Complex anatomies per preprocedural imaging (e.g., persistent left superior vena cava, cor triatriatum);\n7. Recent (≤30 days) sedative\u002Fanalgesic exposure.\"",{"count":252,"type":21},120,[24],"I. Background Atrial fibrillation, a common type of arrhythmia, is often treated with radiofrequency catheter ablation, a minimally invasive procedure that helps restore a normal heart rhythm. While this surgery is typically performed under \"light sedation\" (where patients remain semi-awake) and allows for quick recovery, many patients still experience significant anxiety during the procedure due to pain, unfamiliar surroundings, or concerns about surgical risks. Research shows that anxiety not only makes people more sensitive to pain but can also trigger physical tension, irregular breathing, and even affect the precision of the surgeon's movements-potentially prolonging the procedure or increasing the risk of complications.\n\nCurrently, hospitals primarily rely on sedatives and painkillers to ease patient discomfort. However, these medications may cause side effects like low blood pressure or slowed breathing, which can be particularly dangerous for older patients with heart conditions. As a safer alternative, non-drug approaches like music therapy are gaining attention. Studies suggest that listening to music can reduce anxiety and pain in other medical settings (such as during biopsies or pre-surgery preparation), likely because it helps the body relax, reduces stress hormones, or distracts the mind. Yet, there's limited evidence on whether music can provide similar benefits during atrial fibrillation catheter ablation, especially in helping patients maintain steady breathing.\n\nTo address this gap, the present study aims to explore how music interventions affect anxiety, pain, and breathing stability in patients undergoing atrial fibrillation catheter ablation. Investigators hope this research will offer practical solutions to improve patient comfort, reduce reliance on medications, and enhance surgical safety, while also providing scientific support for expanding non-drug therapies in cardiac procedures.\n\nII. Study Purpose To evaluate whether music during atrial fibrillation catheter ablation helps reduce patients' anxiety and pain, stabilize breathing, and improve satisfaction for both patients and doctors while making the procedure more efficient.\n\nIII. Study Design Prospective randomized controlled trial\n\nIV. Study Plan\n\n1. Participants\n\n   Inclusion Criteria:\n   * First-time atrial fibrillation ablation patients (aged 18-80) following clinical guidelines.\n   * Willing to participate and sign consent.\n\n   Exclusion Criteria:\n   * Mental health issues (e.g., anxiety requiring medication, sleep disorders).\n   * Hearing loss, communication difficulties, or need for general anesthesia.\n   * Prior heart surgeries or catheter ablation, complex heart anatomy, or recent pain\u002Fsedation medication use.\n\n   Grouping: Patients split evenly into \"music group\" or \"control group,\" based on atrial fibrillation type (persistent or paroxysmal).\n2. Sample Size 60 patients\u002Fgroup (120 total) will be chosen.\n3. Blinding\n\n   * Patients and doctors know the group assignment (music or no music).\n   * Researchers assessing pain\u002Fanxiety and statisticians are blinded.\n4. Data Collected\n\n   * Basic info (age, weight, education).\n   * Health history (smoking, heart conditions, medications).\n   * Atrial fibrillation details (type, duration).\n   * Test results (e.g., heart size, kidney function).\n5. Pain\u002FSedation Protocol\n\n   * Light sedation with fentanyl (adjusted as needed).\n   * Extra midazolam given if heart rhythm needs electric correction.\n6. Ablation Procedure\n\n   * For Paroxysmal atrial fibrillation: Isolate lung veins.\n   * For Persistent atrial fibrillation: Extra ablation lines on heart walls.\n   * Power and pressure settings vary by heart area to balance safety and effectiveness.\n7. Music Intervention\n\n   * Music Group: Patients pick preferred music (classical, pop, etc.) played at 50-60 dB during procedure.\n   * Control Group:\\*No music.\n8. Outcomes Measured\n\nMain Outcomes:\n\n* Pain: Rated by patients post-surgery using a face-based scale.\n* Anxiety: Measured before and after surgery with a standard questionnaire.\n\nSecondary Outcomes:\n\n* Breathing Stability: Breathing rate, pauses, and patterns.\n* Procedure Efficiency: Surgery duration, X-ray time, success rate.\n* Complications: Bleeding, heart injury, stroke risk.\n* Drug Use: Amount of painkillers needed.\n* Satisfaction: Ratings from patients and doctors (1-5 scale).\n* Doctor Fatigue: Self-reported by surgeons.",[61,27,256],"Pain Management","2025-07-06",{"date":259,"type":38},"2025-07-10",{"date":257,"type":38},{"date":262,"type":21},"2026-12-30",{"name":264,"class":45},"Shaoxing People's Hospital",{"id":266,"slug":267,"hasResults":11,"nctId":268,"briefTitle":269,"officialTitle":269,"acronym":4,"eligibilityCriteria":270,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":271,"targetDuration":4,"studyType":22,"phases":273,"briefSummary":274,"conditions":275,"keywords":281,"overallStatus":155,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":289,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":4},"100590589","empiric-pulsed-field-pulmonary-vein-isolation-during-atrial-tachycardia-ablation-in-adults-with-congenital-heart-disease-100590589","NCT06969378","Empiric Pulsed Field Pulmonary Vein Isolation During Atrial Tachycardia Ablation in Adults With Congenital Heart Disease","Inclusion Criteria:\n\n* Adult patients (\\>= 18 years of age) with repaired or unrepaired congenital heart disease and a history of sustained (\\>30 seconds) AT\n\nExclusion Criteria:\n\n* History of sustained AF and\u002For previous catheter or surgical pulmonary vein isolation.",{"count":272,"type":21},30,[24],"This is a prospective, single-arm intervention trial whereby we will test the safety and efficacy of performing pulmonary vein isolation (PVI) using pulsed field ablation (PFA) in adult patients with congenital heart disease (CHD) who are presenting for atrial tachycardia (AT) ablation.",[68,276,277,278,279,280,27],"Atrial Tachycardia","Atrial Flutter","Congenital Heart Disease","Pulmonary Vein Isolation","Pulsed Field Ablation",[121,282,283,284,285,286,287,32],"atrial tachycardia","atrial flutter","pulsed field ablation","congenital heart disease","adult congenital heart disease","pulmonary vein isolation","2025-05-05",{"date":290,"type":38},"2025-05-13",{"date":292,"type":21},"2025-07-01",{"date":294,"type":21},"2026-06-30",{"name":296,"class":45},"Boston Children's Hospital",{"id":298,"slug":299,"hasResults":11,"nctId":300,"briefTitle":301,"officialTitle":302,"acronym":303,"eligibilityCriteria":304,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":305,"enrollmentInfo":306,"targetDuration":4,"studyType":22,"phases":307,"briefSummary":308,"conditions":309,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":315,"startDateStruct":317,"completionDateStruct":319,"leadSponsor":320,"locationsCount":46},"100558850","preventive-catheter-ablation-for-ventricular-arrhythmias-in-patients-with-end-stage-heart-failure-100558850","NCT06556485","Preventive Catheter Ablation for Ventricular arrhythmiaS in Patients With End-sTage Heart faiLure","Preventive Catheter Ablation for Ventricular arrhythmiaS in Patients With End-sTage Heart faiLure rEfferred for Heart Transplantation eValuaTion (CASTLE-VT)","CASTLE-VT","Inclusion Criteria:\n\n1. Ischemic cardiomyopathy with left ventricular ejection fraction ≤ 35% (measured in the last 6 weeks prior to enrollment)\n2. Eligible for heart transplantation due to end-stage heart failure\n3. NYHA class ≥ III\n4. Impaired functional capacity or inability to exercise\n5. Indication for ICD therapy due to primary prevention\n6. Implanted ICD or ICD implantation within 3 months after randomization\n7. The patient is willing and able to comply with the protocol and has provided written informed consent\n8. Age ≥ 18 years\n\nExclusion Criteria:\n\n1. Previous catheter ablation for ventricular arrhythmias\n2. Previous appropriate ICD-therapy for ventricular arrhythmias\n3. Acute coronary syndrome, cardiac surgery, angioplasty, or cerebrovascular accident within 4 weeks prior to enrollment\n4. Untreated hypothyroidism or hyperthyroidism\n5. Woman currently pregnant, breastfeeding, or not using reliable contraceptive measures during fertility age\n6. Mental or physical inability to participate in the study\n7. Listed as \"high urgent\" for heart transplantation\n8. Cardiac assist device implanted\n9. Planned cardiovascular intervention\n10. Life expectancy ≤ 12 month\n11. Uncontrolled hypertension\n12. Requirement for dialysis due to end-stage renal failure","99 Years",{"count":201,"type":21},[24],"CASTLE-VT is a randomized evaluation of prophylactic ablative treatment of arrhythmogenic ventricular scar in patients referred for HTx evaluation and diagnosed with ICM. Ablation will be performed with the use of a substrate-based approach in which the myocardial scar is mapped and ablated while the heart remains predominantly in sinus rhythm. The primary end point is the composite of all-cause mortality, worsening of HF requiring prioritized transplantation or LVAD implantation. The main secondary study end points are all-cause mortality, cardiovascular mortality, incidence of implantable cardioverter-defibrillator (ICD) therapy, hospitalizations, Quality of life, time to first ICD therapy, number of device-detected ventricular tachycardia\u002Fventricular fibrillation episodes, LV function, and exercise tolerance. CASTLE-VT will randomize 160 patients with a follow up period of 2 years.",[150,310,311,27,312,313],"Arrhythmia, Ventricular","Cardiomyopathy Ischemic","Heart Transplantation","Left Ventricular Assist Device","2024-12-01",{"date":316,"type":38},"2024-12-04",{"date":318,"type":38},"2024-09-13",{"date":160,"type":21},{"name":321,"class":45},"Heart and Diabetes Center North-Rhine Westfalia",{"id":323,"slug":324,"hasResults":11,"nctId":325,"briefTitle":326,"officialTitle":327,"acronym":328,"eligibilityCriteria":329,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":330,"targetDuration":4,"studyType":22,"phases":332,"briefSummary":333,"conditions":334,"keywords":337,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":342,"startDateStruct":344,"completionDateStruct":346,"leadSponsor":348,"locationsCount":46},"100569194","cavo-tricuspid-isthmus-block-durability-after-pulsed-electric-field-ablation-100569194","NCT06691074","Cavo-Tricuspid Isthmus Block Durability After Pulsed Electric Field Ablation","Systematic Assessment of the Acute Cavo-Tricuspid Isthmus Block Durability After Pulsed Electric Field Ablation","SECTION","Inclusion Criteria:\n\n* patients with paroxysmal AF undergoing PVI by PEF energy with documented typical atrial flutter or patients with persistent AF in whom catheter ablation of CTI is planned as a part of a complex procedure\n* Age ≥ 18 years at the time of study enrollment\n* Signed informed consent\n\nExclusion Criteria:\n\n* \\- LA diameter \\> 65 mm (measured in the parasternal long-axis view)\n* History of CTI ablation in the past\n* History of cardiac valve surgery\n* Significant valvular defect\n* Age below 18 years\n* Pregnancy, breastfeeding\n* Any disease with a life expectancy \\<1 year\n* Uncorrected congenital heart disease or valvular obstruction\n* Active myocarditis\n* Untreated hypothyroidism or hyperthyroidism\n* Recipient of any major organ transplant (e.g., lung, liver, heart)\n* HIV positivity with a survival expectancy of less than five years due to HIV\n* Chronic dialysis treatment\n* Unwillingness to participate.",{"count":331,"type":21},150,[24],"This study seeks to assess the acute durability of the CTI block when PEF energy is used. Second goal is to establish the optimal waiting time for the conduction recovery after PEF CTI ablation and to assess the utility of routine adenosine testing for dormant conduction. Moreover, this study aims to investigate the differences in acute efficacy and adverse events (hemolysis, coronary vasospasm) between the two available configurations (basket or flower) of the pentaspline Farawave catheter (Farapulse-Boston Scientific Inc, USA).",[335,336,27],"Flutter, Atrial","Cavotricuspid Isthmus Dependent Right Atrial Flutter",[338,339,340],"Pulsed Electric Field","Cavo-tricuspid Isthmus","Biderectional Block","2024-11-14",{"date":343,"type":38},"2024-11-15",{"date":345,"type":38},"2024-09-16",{"date":347,"type":21},"2025-12-31",{"name":349,"class":350},"Institute for Clinical and Experimental Medicine","OTHER_GOV",{"id":352,"slug":353,"hasResults":11,"nctId":354,"briefTitle":355,"officialTitle":356,"acronym":357,"eligibilityCriteria":358,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":113,"enrollmentInfo":359,"targetDuration":4,"studyType":361,"phases":4,"briefSummary":362,"conditions":363,"keywords":365,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":368,"startDateStruct":370,"completionDateStruct":372,"leadSponsor":374,"locationsCount":46},"100560185","outcomes-of-pfa-vs-rfa-for-patients-with-psvt-a-retrospective-and-propensity-score-matching-study-100560185","NCT06573853","Outcomes of PFA Vs. RFA for Patients with PSVT: a Retrospective and Propensity Score Matching Study","The Safety and Efficiency of Pulsed Field Ablation and Radiofrequency Ablation in the Treatment of Paroxysmal Supraventricular Tachycardia：a Retrospective and Propensity Score Matching Study","PFA*RFA*PSVT","Inclusion Criteria:\n\n1. Patients with symptomatic PSVT including: atrioventricular nodal re-entrant tachycardia (AVNRT), atrioventricular re-entrant tachycardia (AVRT);\n2. Age range: 18 years old ≤ age ≤ 80 years old, with no gender restriction;\n3. Willing to receive the examinations and testings during one year follow-up required by the protocol;\n4. Voluntary signed informed consent.\n\nExclusion Criteria:\n\n1. Organic heart disease;\n2. History of cardiac surgery;\n3. Previous failed ablation of PSVT;\n4. Presence of any implants, such as a permanent pacemaker;\n5. Patients with invasive systemic infections or advanced malignant tumors;\n6. Contraindications for septal puncture or retrograde transaortic access surgery;\n7. Any condition that makes the use of heparin or aspirin inappropriate;\n8. Pregnant or lactating women;\n9. Inability to fully comply with the study procedures and follow-ups or to provide their own informed consent;\n10. Coexistence with other arrhythmias, such as atrial fibrillation.",{"count":360,"type":21},428,"OBSERVATIONAL","The goal of this retrospective study is to compare the long-term follow-up outcomes of pulses field ablation (PFA) Vs. radiofrequency ablation (RFA) for the patients with paroxysmal supraventricular tachycardia (PSVT). The main question to answer is:\n\nDoes the PFA was more effecient and safer that RFA for treatment of PSVT during procedure and after 1-year follow-up? Researchers will compare the acute and long-term efficiency and safety between PFA and RFA.\n\n1. Recieved PFA or RFA 1 year ago\n2. Finish the visit to the clinic at 1, 3, 6, 12 months for examinations and blood testings\n3. Patients recieved PFA and PFA under propensity matched comparison according to differen variety of PSVT",[364,27],"Paroxysmal Supraventricular Tachycardia",[364,280,366],"Radiofrequency Ablation","2024-10-22",{"date":369,"type":38},"2024-10-24",{"date":371,"type":38},"2022-10-11",{"date":373,"type":21},"2025-06-30",{"name":375,"class":45},"Caijie Shen",{"id":377,"slug":378,"hasResults":11,"nctId":379,"briefTitle":380,"officialTitle":381,"acronym":4,"eligibilityCriteria":382,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":383,"targetDuration":4,"studyType":361,"phases":4,"briefSummary":385,"conditions":386,"keywords":389,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":394,"lastUpdatePostDateStruct":395,"startDateStruct":397,"completionDateStruct":399,"leadSponsor":401,"locationsCount":403},"100562397","hybrid-score-to-predict-otva-soo-in-patients-with-wide-basal-qrs-100562397","NCT06602635","Hybrid Score to Predict OTVA-SOO in Patients with Wide Basal QRS","A Hybrid Score to Predict the Origin of Outflow Tract Ventricular Arrhythmias in Patients with Intraventricular Conduction Disorders or Paced Rhythm","Inclusion Criteria:\n\n* ventricular arrhythmia with a morphology indicating an outflow tract origin and a wide basal QRS complex\n* a QRS width greater than 110 ms was considered wide\n* willing and capable of providing written informed consent to the study\n\nExclusion Criteria:\n\n* catether ablation procedure was unsuccessful\n* infrequent arrhythmia requiring ablation guided by pacemapping.",{"count":384,"type":21},100,"Outflow tract ventricular arrhythmia (OTVA) is the most common type of ventricular arrhythmia, and catheter ablation (CA) is the primary treatment option for patients experiencing symptoms. Accurately identifying the origin site of OTVA is essential for effective catheter ablation, minimizing procedural risks, and enhancing treatment success. However, most studies that developed algorithms or scoring systems for distinguishing OTVA origins excluded participants with structural heart disease and those with paced rhythms from their study groups. A recent prospective evaluation of a hybrid score (HS) that integrates both clinical and ECG data to predict OTVA-SOO, including patients with cardiac implantable electronic devices and those with structural heart disease in our study.\n\nThe presented study aimed to assess the effectiveness of the previously described hybrid algorithm in predicting OTVA-SOO in a patient population characterized by a wide basal QRS due to intraventricular conduction defects or paced rhythms.\n\nThe Hybrid Score The Hybrid Score (HS), involves a sum of points based on clinical and ECG characteristics. Points are assigned as follows: one point each for being over 50 years old, male, and having arterial hypertension. ECG-based points are allocated according to QRS transition: 3 points for a transition in V1, 2 points for V2, 1 point for V3 if the R-wave in V3 is greater than 1 mV; 1 point is subtracted if V3 has an R-wave less than 1 mV, and further deductions or additions apply for transitions up to V6. A score ≤ 1 suggests an RVOT origin, whereas ≥ 2 suggests an LVOT origin.\n\nECGs were recorded with a standard configuration at a 25 mm\u002Fs sweep speed.\n\nPremature Ventricular Contraction (PVC) Ablation Activation mapping of spontaneous OTVAs was conducted. The procedure aimed to abolish spontaneous OTVAs, with the site of ablation marking the site of origin (SOO).\n\nCollected data\n\n* Patient Information and Consent (procedure must be done within 60 days of consent)\n* Demographics (age, gender, etc.)\n* Vital signs (length, weight, etc.)\n* Medical history, including cardiovascular risk factors, cardiomyopathy and drugs\n* ECG data\n* Echocardiographic data (left ventricular ejection fraction and left ventricular end-diastolic diameter)\n* Procedure data (number of radiofrequency applications, site of effective ablation, total radiofrequency time, total fluoro time, points mapping, procedure time)\n* Adverse Events",[387,388,27],"ECG","Ventricular Arrhythmias",[390,391,392,393],"Ventricular extrasystole","Premature ventricular complex","ecg","outflow tract ventricular arrhythmias","2024-09-21",{"date":396,"type":38},"2024-09-24",{"date":398,"type":38},"2022-01-04",{"date":400,"type":21},"2024-10-23",{"name":402,"class":45},"Centro Medico Teknon",6,{"id":405,"slug":406,"hasResults":11,"nctId":407,"briefTitle":408,"officialTitle":409,"acronym":410,"eligibilityCriteria":411,"healthyVolunteers":412,"sex":17,"minAge":413,"maxAge":414,"enrollmentInfo":415,"targetDuration":417,"studyType":361,"phases":4,"briefSummary":418,"conditions":419,"keywords":427,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":443,"lastUpdatePostDateStruct":444,"startDateStruct":446,"completionDateStruct":448,"leadSponsor":449,"locationsCount":46},"100561522","role-of-endomyocardial-biopsy-and-aetiology-based-treatment-in-pediatric-patients-with-inflammatory-heart-disease-in-arrhythmic-and-non-arrhythmic-clinical-presentations-an-integrated-approach-for-the-optimal-diagnostic-and-therapeutic-management-myoped-100561522","NCT06591260","Role of Endomyocardial Biopsy and Aetiology-based Treatment in Pediatric Patients with Inflammatory Heart Disease in Arrhythmic and Non-arrhythmic Clinical Presentations: an Integrated Approach for the Optimal Diagnostic and Therapeutic Management (MYOPED)","Role of Endomyocardial Biopsy and Aetiology-based Treatment in Pediatric Patients with Inflammatory Heart Disease in Arrhythmic and Non-arrhythmic Clinical Presentations: an Integrated Approach for the Optimal Diagnostic and Therapeutic Management","MYOPED","Inclusion Criteria:\n\n* Written informed consent.\n* Age \\< 18 years.\n* Clinically suspected myocarditis.\n* Enrollment performed by one of the participating Centers.\n\nExclusion Criteria:\n\n* Absence of written informed consent.\n* Age \\> 18 years (adults)",true,"0 Years","17 Years",{"count":416,"type":21},20,"30 Years","Myocarditis is a complex inflammatory disease, usually occurring secondary to viral infections, autoimmune processes or toxic agents. Clinical presentations are multiple, including chest-pain, heart failure and a broad spectrum of arrhythmias. In turn, outcome is largely unpredictable, ranging from mild self-limiting disease, to chronic stage and progressive evolution towards dilated cardiomyopathy, to rapid adverse outcome in fulminant forms. Subsequently, myocarditis is often underdiagnosed and undertreated, and optimal diagnostic and therapeutic strategies are still to be defined. This study, both retrospective and prospective, originally single-center and subsequently upgraded to multicenter, aims at answering multiple questions about myocarditis, with special attention to its arrhythmic manifestations.\n\nOptimal diagnostic workflow is still to be defined. In fact, although endomyocardial biopsy (EMB) is still the diagnostic gold standard, especially for aetiology identification, it is an invasive technique. Furthermore, it may lack sensitivity because of sampling errors. By converse, modern imaging techniques - cardiac magnetic resonance (CMR) in particular - have been proposed as alternative or complementary diagnostic tool in inflammatory heart disease. Other noninvasive diagnostic techniques, like delayed-enhanced CT (DECT) scan or position emission tomography (PET) scan, are under investigation.\n\nBiomarkers to identify myocarditis aetiology, predisposition, prognosis and response to treatment are still to be defined.\n\nArrhythmic myocarditis is largely underdiagnosed and uninvestigated. Importantly, myocarditis presenting with arrhythmias requires specific diagnostic, prognostic and therapeutic considerations. At the group leader hospital, which is an international referral center for ventricular arrhythmias management and ablation, a relevant number of patients with unexplained arrhythmias had myocarditis as underlying aetiology. The experience of a dedicated third-level center is going to be shared with other centers, to considerably improve knowledge and management of arrhythmic myocarditis.\n\nThe role of CMR, as well as alternative noninvasive imaging techniques, in defining myocarditis healing is a relevant issue. In particular, optimal timing for follow-up diagnostic reassessment is still to be defined, in patients with myocarditis at different inflammatory stages, either with or without aetiology-dependent treatment.\n\nUniformly-designed studies are lacking, to compare myocarditis among different patient subgroups, differing by variables like: clinical presentations, myocarditis stage, associated cardiac or extra-cardiac diseases, aetiology-based treatment, associated arrhythmic manifestations, diagnostic workup, and devices or ablation treatment.",[420,421,422,423,424,147,425,426,27],"Myocarditis","Ventricular Arrhythmia","Inflammatory Cardiomyopathy","Genetic Predisposition","Autoimmunity","Cardiomyopathies","Immunosuppresion",[420,428,429,430,431,432,433,434,435,436,437,438,439,440,441,442],"Ventricular arrhythmias","Arrhythmias","Arrhythmogenic inflammatory cardiomyopathy","Endomyocardial biopsy","Cardiac magnetic resonance","Ablation","Positron emission tomography","Electroanatomical mapping","Immunosuppressive therapy","Arrhythmic risk stratification","Genetic predisposition","Environment","Implantable cardioverter defibrillator","Implantable loop recorder","Multicenter","2024-09-11",{"date":445,"type":38},"2024-09-19",{"date":447,"type":38},"2013-01-01",{"date":162,"type":21},{"name":450,"class":45},"Scientific Institute San Raffaele",{"id":452,"slug":453,"hasResults":11,"nctId":454,"briefTitle":455,"officialTitle":455,"acronym":456,"eligibilityCriteria":457,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":458,"targetDuration":460,"studyType":361,"phases":4,"briefSummary":461,"conditions":462,"keywords":465,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":467,"lastUpdatePostDateStruct":468,"startDateStruct":469,"completionDateStruct":471,"leadSponsor":473,"locationsCount":46},"100402555","role-of-endomyocardial-biopsy-and-aetiology-based-treatment-in-patients-with-inflammatory-heart-disease-in-arrhythmic-and-non-arrhythmic-clinical-presentations-an-integrated-approach-for-the-optimal-diagnostic-and-therapeutic-management-100402555","NCT04521790","Role of Endomyocardial Biopsy and Aetiology-based Treatment in Patients With Inflammatory Heart Disease in Arrhythmic and Non-arrhythmic Clinical Presentations: an Integrated Approach for the Optimal Diagnostic and Therapeutic Management","MYOCAR","Inclusion Criteria:\n\n* Written informed consent.\n* Age ≥ 18 years.\n* Clinically suspected myocarditis.\n* Enrollment performed by one of the participating Centers.\n\nExclusion Criteria:\n\n* Absence of written informed consent.\n* Age \\\u003C 18 years (paediatric population).",{"count":459,"type":21},1000,"10 Years","Myocarditis is a complex inflammatory disease, usually occurring secondary to viral infections, autoimmune processes or toxic agents. Clinical presentations are multiple, including chest-pain, heart failure and a broad spectrum of arrhythmias. In turn, outcome is largely unpredictable, ranging from mild self-limiting disease, to chronic stage and progressive evolution towards dilated cardiomyopathy, to rapid adverse outcome in fulminant forms. Subsequently, myocarditis is often underdiagnosed and undertreated, and optimal diagnostic and therapeutic strategies are still to be defined. This study, both retrospective and prospective, originally single-center and subsequently upgraded to multicenter, aims at answering multiple questions about myocarditis, with special attention to its arrhythmic manifestations.\n\n1. Optimal diagnostic workflow is still to be defined. In fact, although endomyocardial biopsy (EMB) is still the diagnostic gold standard, especially for aetiology identification, it is an invasive technique. Furthermore, it may lack sensitivity because of sampling errors. By converse, modern imaging techniques - cardiac magnetic resonance (CMR) in particular - have been proposed as alternative or complementary diagnostic tool in inflammatory heart disease. Other noninvasive diagnostic techniques, like delayed-enhanced CT (DECT) scan or position emission tomography (PET) scan, are under investigation.\n2. Biomarkers to identify myocarditis aetiology, predisposition, prognosis and response to treatment are still to be defined.\n3. Arrhythmic myocarditis is largely underdiagnosed and uninvestigated. Importantly, myocarditis presenting with arrhythmias requires specific diagnostic, prognostic and therapeutic considerations. At the group leader hospital, which is an international referral center for ventricular arrhythmias management and ablation, a relevant number of patients with unexplained arrhythmias had myocarditis as underlying aetiology. The experience of a dedicated third-level center is going to be shared with other centers, to considerably improve knowledge and management of arrhythmic myocarditis.\n4. The role of CMR, as well as alternative noninvasive imaging techniques, in defining myocarditis healing is a relevant issue. In particular, optimal timing for follow-up diagnostic reassessment is still to be defined, in patients with myocarditis at different inflammatory stages, either with or without aetiology-dependent treatment.\n5. Uniformly-designed studies are lacking, to compare myocarditis among different patient subgroups, differing by variables like: clinical presentations, myocarditis stage, associated cardiac or extra-cardiac diseases, aetiology-based treatment, associated arrhythmic manifestations, diagnostic workup, and devices or ablation treatment.",[420,463,422,423,424,147,425,464,27],"Ventricular Arrythmia","Immunosuppression",[420,428,429,430,431,432,433,434,466,435,436,437,438,439,440,441,442],"Cardiac imaging","2024-09-07",{"date":445,"type":38},{"date":470,"type":38},"2018-01-30",{"date":472,"type":21},"2035-12-31",{"name":450,"class":45},{"id":475,"slug":476,"hasResults":11,"nctId":477,"briefTitle":478,"officialTitle":479,"acronym":480,"eligibilityCriteria":481,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":113,"enrollmentInfo":482,"targetDuration":484,"studyType":361,"phases":4,"briefSummary":485,"conditions":486,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":487,"lastUpdatePostDateStruct":488,"startDateStruct":490,"completionDateStruct":492,"leadSponsor":494,"locationsCount":496},"100498999","af-ablation-with-high-power-short-duration-rf-100498999","NCT05777551","AF Ablation With High Power Short Duration RF","Atrial Fibrillation Ablation by Means of Very High Power Short Duration (AIR HPSD Registry)","AIR HPSD","Inclusion Criteria:\n\n* Patients with paroxysmal\u002Fpersistent AF who signed the informed consent\n* Patients on active oral anticoagulation\n\nExclusion Criteria:\n\n* Previous ablation for AF\n* Patients with LVEF\\\u003C35%\n* Women potentially pregnant\n* Contraindications to X-ray exposure\n* Congenital heart disease or cardiac surgery within 1 month",{"count":483,"type":21},850,"12 Months","This is a prospective, multi-center, research study designed to evaluate the safety and efficacy of pulmonary vein (PV) isolation with high power short duration radiofrequency energy in patients with paroxysmal\u002Fpersistent atrial fibrillation (AF).\n\nSubjects with paroxysmal\u002Fpersistent AF will undergo catheter ablation using commercially approved devices (mapping system and catheters).\n\nPatients will be followed up for 12 months to measure the recurrence of AF and its predictors. The primary endpoint will be to investigate the association between clinical and procedural characteristics and the efficacy and the safety of PVI performed with HPSD.\n\nAt least 850 consecutive will be enrolled to have an adequate statistical power for the analysis of the primary endpoint. We assume that the freedom form AF recurrence at 12 months will be 80%. Expected R\\^2 (Cox-Snell) 0.1. Candidate variables to be included in the model:10. Shrinkage level: 0.9. Based on these assumption the minimum number of patients is 850 with 170 events and EPP 17.",[68,27],"2024-03-02",{"date":489,"type":38},"2024-03-05",{"date":491,"type":38},"2023-01-01",{"date":493,"type":21},"2027-12-31",{"name":495,"class":45},"Clinica Mediterranea",9,{"id":498,"slug":499,"hasResults":11,"nctId":500,"briefTitle":501,"officialTitle":501,"acronym":502,"eligibilityCriteria":503,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":504,"targetDuration":4,"studyType":361,"phases":4,"briefSummary":506,"conditions":507,"keywords":509,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":513,"lastUpdatePostDateStruct":514,"startDateStruct":516,"completionDateStruct":518,"leadSponsor":520,"locationsCount":46},"100341718","japanese-catheter-ablation-registry-100341718","NCT03729232","Japanese Catheter Ablation Registry","J-AB","Inclusion Criteria:\n\n* Patients treated with catheter ablation in Japan\n\nExclusion Criteria:\n\n* Patients who refused to consent",{"count":505,"type":21},400000,"Japanese Cather Ablation (J-AB) Registry is a voluntary nationwide registry, performed by Japanese Heart Rhythm Society, collaborated with the National Cerebral and Cardiovascular Center. The objectives of this registry are to observe and describe developments in the catheter ablation treatment of arrhythmia in Japan and to provide reliable information on the type of activity performed and the facilities available in Japanese arrhythmia units.",[27,508],"Cardiac Arrhythmias",[27,508,510,511,512],"Registry","Complication","REDCap","2023-11-09",{"date":515,"type":38},"2023-11-13",{"date":517,"type":38},"2017-07-01",{"date":519,"type":21},"2030-03-31",{"name":521,"class":45},"National Cerebral and Cardiovascular Center, Japan"]